Shares of Cell Therapeutics Inc. (NYSE: CTIC) continued to rise by gaining 15 cents to close at $1.46 after announcing that the Eurpean Medicines Agency's Committee for Medicinal Products for Human Use may issue an opinion of the company's Marketing Authorization Application for Pixuvri in mid-February.